Published on 1 Sep 2022 on American City Business Journals
Amid Huntington's disease hopes and failures, Annexon targets new approach
There are no approved therapies for people with Huntington's disease, an inherited neurodegenerative...
NASDAQ.ANNX price evolution
NASDAQ.OSS price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free